REVAXIS

This brand name is authorized in Austria, France, Ireland, Malta, Netherlands, United Kingdom

Active ingredients

The drug REVAXIS contains a combination of these active pharmaceutical ingredients (APIs):

1 Purified diphtheria toxoid UNII 3U7E3O07S8 - CORYNEBACTERIUM DIPHTHERIAE

Read about Diphtheria toxoid

2 Purified tetanus toxoid UNII K3W1N8YP13 - CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Tetanus toxoid

3 Inactivated poliovirus vaccine type I UNII 0LVY784C09 - POLIOVIRUS TYPE 1 ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Poliomyelitis, serotype 1

4 Inactivated poliovirus vaccine type II UNII 23JE9KDF4R - POLIOVIRUS TYPE 2 ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Poliomyelitis, serotype 2

5 Inactivated poliovirus vaccine type III UNII 459ROM8M9M - POLIOVIRUS TYPE 3 ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Poliomyelitis, serotype 3

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J07CA01	Diphtheria-poliomyelitis-tetanus	J Antiinfectives for systemic use → J07 Vaccines → J07C Bacterial and viral vaccines, combined → J07CA Bacterial and viral vaccines, combined
Discover more medicines within J07CA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: FR	Base de données publique des médicaments	Identifier(s): 60917345
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 73745
Country: MT	Medicines Authority	Identifier(s): AA1438/05501, AA1438/05502, AA565/37901, AA573/01901
Country: NL	Z-Index G-Standaard	Identifier(s): 14818434
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 67830